Laval, Québec, September 24, 2026— Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began.

"The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these patients are treated. Altasciences has been an exceptional partner in our FDA journey.

Their ability to support us through drug product development and manufacturing, regulatory preparation, and now our Phase I clinical study has provided exactly the kind of integrated partnership an emerging pharmaceutical company needs. Reaching the Phase I clinical trial stage is an important milestone for RhineX, and Altasciences has been integral to 4B reaching this milestone.”

RhineX is a first-in-class medicated nasal rinse platform, with patents both approved and pending, designed to deliver medication throughout the nasal cavity and provide a simpler approach to steroid nasal irrigation for patients and healthcare providers. 4B is developing the therapeutic for patients with allergic rhinitis and chronic sinusitis, building on the use of steroid rinses in ENT and allergy practice.

The collaboration focused on developing and optimizing low- and high-dose steroid formulations for a 4B-patented sachet designed for nasal irrigation. Altasciences developed and evaluated multiple prototype formulations using innovative approaches and techniques, then manufactured R&D batches and packaged them into the 4B-proprietary sachets for testing.

The program also included analytical method development and qualification, accelerated stability testing, packaging evaluation, CMC consulting, including support for specification setting, and cGMP and quality assurance support to help advance the selected formulation toward clinical use.  

“We’re proud to see the work completed by our Harleysville team help move RhineX into the clinic,” said Robert Sabelli, President, Drug Development Solutions at Altasciences. “This is where an integrated development model can make a real difference, allowing a program to move from formulation and manufacturing into clinical and bioanalytical execution with continuity across teams. We look forward to continuing to support 4B as RhineX advances.”

The Phase I clinical study will be conducted at Altasciences’ site in Los Angeles, CA, with bioanalytical support from its laboratory in Greater Montréal, QC, and broader CRO services supporting the program. 

About Altasciences
Altasciences is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across nonclinical, clinical, bioanalytical, and formulation and manufacturing services. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept—helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. 

 

• Read more about Rapid Formulation Pivot Preserves GLP Study Timeline

Laval, Québec, August 4, 2026 — Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space.

The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines. 

“With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey,” said Anuji Abraham, Senior Director, Pharmaceutical Development, CDMO Services, Altasciences. “This enhances continuity across nonclinical and clinical programs, helping clients navigate key development milestones more efficiently and effectively.”

The enhanced laboratory supports phase-appropriate, target product profile (TPP)-driven formulation screening, tailored to both therapeutic areas and routes of administration while remaining agnostic to both. Capabilities include formulation development for small molecules, peptides, and complex modalities, as well as non-GLP and GLP toxicology samples for nonclinical studies. 

Advanced screening models and Integrated analytical testing support nonclinical and clinical readiness, in addition to real-time formulation decisions. By operating in a non-GLP R&D environment, clients will gain flexibility to design and optimize their products before transitioning into regulated studies. 

“This expansion is not just about building additional space,” said Robert Sabelli, Co-Chief Operating Officer, Altasciences. “By continuing to invest in our team, we are growing our scientific talent and connecting our capabilities earlier in the development cycle to better support our clients—and ultimately, the patients they serve.”

About Altasciences
Altasciences is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across nonclinical, clinical, bioanalytical, and formulation and manufacturing services. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept—helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visit altasciences.com.

Julie-Ann Cabana
Altasciences
media@altasciences.com
 

• Read more about CLINDMO: Where Clinical Innovation Meets Manufacturing Excellence

• Read more about A Novel Approach for Improved Bioavailability in Solid Dosage Forms

• Read more about Spray Drying Nanosuspensions